Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy

Abstract Background Cystic fibrosis (CF) is a genetic disorder causing poor mucociliary clearance in the airways and subsequent respiratory infection. The recently approved triple therapy Elexacaftor–Tezacaftor–Ivacaftor (ETI) has significantly improved lung function and decreased airway infection i...

Full description

Bibliographic Details

Published in:	Respiratory Research
Main Authors:	Christian Martin, Douglas V. Guzior, Cely T. Gonzalez, Maxwell Okros, Jenna Mielke, Lienwil Padillo, Gabriel Querido, Marissa Gil, Ryan Thomas, Marc McClelland, Doug Conrad, Stefanie Widder, Robert A. Quinn
Format:	Article
Language:	English
Published:	BMC 2023-12-01
Subjects:	Cystic fibrosis Microbiome Metabolome Neutral models Elexacaftor–Tezacaftor–Ivacaftor Pseudomonas aeruginosa
Online Access:	https://doi.org/10.1186/s12931-023-02630-z